Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s recently launched long-acting version of Copaxone (Copaxone 40mg) point to a 28% NRX switch rate, and a 7% TRx switch rate in the first four weeks since the drug’s launch. We continue to believe that the Street is underappreciating the switch potential of Copaxone 40mg ahead of the patent expiry of Copaxone 20mg at the end of May 2014, and see potential upside to our above-consensus base case switch rate of 32% (see our recent note: Copaxone 3TW Switch Dynamics Underappreciated; Reiterating Buy and Raising TP to $56). Teva remains a favored name amongst our multinational generics universe. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock opened at $49.71 in last session, and closed at $50.02, while the day range of TEVA stock is $49.09-$50.29.The stock showed a positive weekly performance of 2.52%.
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013. For the quarter ended December 31, 2013, Dynavax reported total revenues of $2.8 million compared to $1.8 million for the fourth quarter of 2012. For the year ended December 31, 2013, total revenues were $11.3 million compared to $9.7 million for 2012. Dynavax Technologies Corporation (NASDAQ:DVAX) stock opened at $1.86, in last session and closed at $1.88, by loosed -0.53%. The 52 week range was $0.98-$2.68. Company’s market capitalization is $493.74 million.
A number of firms have modified their ratings and price targets on shares of Endo Health Solutions (NASDAQ:ENDP) recently, Endo Health Solutions had its price target raised by analysts at Citigroup Inc. from $70.00 to $87.00. Endo Health Solutions had its price target raised by analysts at UBS AG from $75.00 to $90.00. They now have a “buy” rating on the stock. Endo Health Solutions Inc (NASDAQ:ENDP) stock loosed -0.96% and finished the last session at $73.05. The EPS of the stock remained -5.58. Company’s market capitalization is $8.45 billion.
Though ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) managed to improve revenues by 113% over the same period last year, it disappointed investors with its earnings. The company reported revenues of $42.2 million for the quarter as compared to $19.9 million declared for the same quarter last year. The company recorded revenues of $41.3 million from research and development on the back of the numerous collaborative agreements, against $17.9 million reported for the same period last year. Licensing and royalty fees accounted for $1 million in revenues. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock opened the session at $50.89, and closed the session at $49.51. The 52 week range of the ISIS stock remained $15.92-$62.66 and the day range was $48.75-$51.34.